Secondary prevention, exemplified by allergen-specific immunotherapy, has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype.

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Some believe that there is a connection among climate change, ozone in outdoor air, and health effects, including asthma. The U.S. Environmental Protection Agency (EPA) released a report in 2020 ...

Its symptoms include coughing ... as environmental allergens. Sudden, acute symptom episodes of either disease can be fatal. About 50 percent of asthma attacks and 30 percent of COPD flare ...

Monoclonal antibody benralizamab was found to be more effective than a dose of steroids when patients had gone to urgent care clinics or emergency departments with acute ... from asthma and COPD ...